CMO Rodman Malcom sold $652.6K in MLYS shares while stock trades 44% below 52-week high; eighth sale at this ticker in 36 months.
Rodman Malcom, Chief Medical Officer, disposed of approximately 22,500 shares across three transactions on consecutive trading days, reducing his direct stake from roughly 70,000 shares to 63,000. This is his eighth open-market sale at Mineralys in the past two years—a clear pattern of consistent equity reduction with no offsetting purchases. The stock currently trades well below its 52-week high, having declined over a longer stretch, yet Malcom's prior five sales at this ticker show mixed near-term timing (two well-timed exits, three where the stock subsequently climbed) but uniformly poor timing at the 90-day horizon, with every prior sale followed by stock gains. The company remains unprofitable with ongoing quarterly losses, presenting a backdrop of fundamental weakness during which the CMO is further lightening his exposure. This filing represents a continuation of the insider's singular focus on exits—he has never made an open-market purchase at Mineralys—suggesting persistent conviction to reduce shares rather than reposition for recovery.